BIOA
BioAge Labs, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 ▼ 1 insider sell $139.4K at $18.75
- Mar 2 ▼ 1 insider sell $150.9K at $20.30
- Mar 2 ▲ The federal district court granted BioAge Labs' motion to dismiss th…
- Mar 24 BioAge Labs reported its full-year 2025 financial results alongside…
- Apr 1 ▼ 1 insider sell $157.1K at $17.81
- Apr 21 ▲ BioAge Labs announced positive Phase 1 results for BGE-102, its oral…
- Apr 21 FDA: BioAge Reports Positive Phase 1 Data for BGE-102, a Novel…
- May 4 FDA: BioAge to Host R&D Day Focused on NLRP3 Inhibition on May…
- May 8 ▲ BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from…
- Jun 16 FDA: BioAge Labs Announces First Participant Dosed in QUELL-CV,…
- Jun 29 to Jun 30 ▼ 2 days of insider sells: $1.6M by 1 insider, avg $25.20
- Oct 12 UBS initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $2.0M.
- InstitutionsBULLISH
Q2 2026: 33 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
12 of 16 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.629 → −$0.731 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +8.6% to 3.73M shares. 4.3 days to cover, ≈8.1% of shares.
- TrendDOWNTREND
20% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $69.8M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $24.6M |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | $17.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $10.1M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $9.7M |
| Walleye Capital LLC | DOUBLED | $8.7M |
| Nuveen, LLC | DOUBLED | $8.6M |
| NORTHERN TRUST CORP | ADD | $8.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is below the lowest target. Median implies +379%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Piper Sandler MAINTAIN | Overweight |
| Nov 9, 2026 | BTIG REITERATE | Buy |
| Oct 12, 2026 | UBS INITIATE | Neutral |
| Sep 9, 2026 | Roth Capital REITERATE | Buy |
| Sep 8, 2026 | BTIG REITERATE | Buy |
| Aug 6, 2026 | BTIG REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Barton Shane Principal Accounting Officer Jun 30, 2026 | EXERCISE | $46.5K |
Barton Shane Principal Accounting Officer Jun 30, 2026 | SELL | $509.2K |
Barton Shane Principal Accounting Officer Jun 30, 2026 | EXERCISE | $33.6K |
Barton Shane Principal Accounting Officer Jun 30, 2026 | EXERCISE | $17.5K |
Barton Shane Principal Accounting Officer Jun 30, 2026 | EXERCISE | $34.4K |
Barton Shane Principal Accounting Officer Jun 29, 2026 | EXERCISE | $100.9K |
Barton Shane Principal Accounting Officer Jun 29, 2026 | SELL | $1.1M |
Barton Shane Principal Accounting Officer Jun 29, 2026 | EXERCISE | $60.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.73 | -$0.79–-$0.67 | -16.1% | $1.0M |
| Next Q | -$0.69 | -$0.78–-$0.58 | -22.9% | $383.3K |
| Current FY | -$2.57 | -$2.65–-$2.50 | -8.2% | $6.9M |
| Next FY | -$2.62 | -$3.12–-$1.93 | -8.5% | $14.5M |
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 3 press releases · 3 bullish · 0 bearish · 5 neutral- NEUTRAL SC 13G/ANov 16, 2026
Cormorant Asset Management filed an amended Schedule 13G disclosing a passive stake of 2,240,605 shares (4.88%) in BioAge Labs as of September 30, 2026, down from a prior filing. The reduction in stake is a routine passive adjustment and does not signal a material change in investment thesis.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 5, 2026
The company completed enrollment in the QUELL-CV Phase 2 cardiovascular trial with topline data…
The key near-term catalyst is QUELL-CV topline data expected in Q4 2026, which will inform dose selection and provide the first proof-of-concept readout for BGE-102 in cardiovascular risk. QUELL-DME…
- NEUTRAL PRESS-RELEASENov 5, 2026
BioAge reported Q3 2026 net loss of $33.5M ($0.73/share), wider than the $20.2M loss a year ago…
QUELL-CV topline data in Q4 2026 is the next major catalyst; a positive readout on hsCRP reduction and biomarker profile could support dose selection and de-risk the program. Monitor cash burn…
- NEUTRAL PRESS RELEASEJun 16, 2026
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of…
No immediate stock-moving catalyst; traders should monitor for topline Phase 2 data in H2 2026. Phase 1 hsCRP reductions were strong, but Phase 2 proof-of-concept is still highly binary and carries…
All BIOA filing & press-release reports (11)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- COURT-RULING reportMar 2, 2026
- PRESS-RELEASE reportJun 16, 2026
- 8-K reportMay 8, 2026
- DEFA14A reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026
- 144 reportApr 1, 2026
- PRESS-RELEASE reportMar 24, 2026
- INST-CLUSTER reportFeb 28, 2026